You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNaproxen
Accession NumberDB00788  (APRD01135)
Typesmall molecule
Groupsapproved
Description

An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
NaprolagNot AvailableIS
NaproxenGermanINN
NaproxèneFrenchINN
NaproxenoSpanishINN
NaproxenumLatinINN
Salts
Name/CAS Structure Properties
Naproxen sodium
Thumb Not applicable DBSALT000949
Brand names
NameCompany
AleveBayer
AlidaseLaboratorios
AlpoxenActavis
AlpronAldril
AnaproxNot Available
ApainMarvic
ApranaxRoche
ApronaxBayer
BonylOrion
BruproxenBruluart
Bumaflex NNycomed
CongexBuxton
DebrilMonserrat
DeproxenDrug International
DysmenalgitKrewel Meuselbach
Ec-naprosynRoche
EmoxEmo-Farm
EmoxenEMO
EurogesicSaval
FabralginaFabra
Feminax UltraBayer
FlogotoneInterpharma
GerinapGerard
HonlowPanion & BF
ImprostanFarmacoop
InflamaxFarmaceutica
InzaAlphapharm
IraxenQuilab
JinkangpuliConba
LexinaxBrisafarma
MelgarHexa
MesselxenBiomep
MobilatSTADA
NAPRELANNot Available
NaprometinRoche
NaprosynRoche
Naprosyn CRAbdi Ibrahim
Naprosyn ECRoche
Naprosyn EnteroRoche
Naprosyn SRRoche
NaprosyneRoche
NaprovalLabinco
NaproxenGlaxoSmithKline
NapruxAndromaco
NeuralpronaLba
NoflamMylan
NopainMedicef
PrexanNew Research
PriaxenRemedica
PrincepsLaser
PronaxenOrion
ProxenGrünenthal
Proxen SRoche
Proxen SRRoche
ReleveGeneral Pharma
ReproDoctor's Chemical Works
ReuxenHelcor
RiproxenBioGenet
SanaproxPerumed
SeladinYSP
ServinaproxNovartis
TarproxenPolfa Tarchomin
TicoflexIncepta
TundraFrasca
XenarElder
Xenar-CRElder
Brand mixtures
Brand NameIngredients
ArthopanNaproxen and Pantoprazole
BrunadolNaproxen and Paracetamol
Lumbal LafrancolNaproxen and Caffeine
MomendolNaproxen and Sulodexide
NeuralgesicNaproxen and Paracetamol
Proxalin-PlusNaproxen and Paracetamol
SumigranNaproxen and Sumatriptan
VimovoNaproxen and Esomeprazole
CategoriesNot Available
CAS number22204-53-1
WeightAverage: 230.2592
Monoisotopic: 230.094294314
Chemical FormulaC14H14O3
InChI KeyCMWTZPSULFXXJA-VIFPVBQESA-N
InChI
InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
IUPAC Name
(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
SMILES
COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O
Mass Specshow(7.95 KB)
Taxonomy
KingdomOrganic Compounds
SuperclassPhenylpropanoids and Polyketides
ClassPhenylpropanoic Acids
SubclassNot Available
Direct parentPhenylpropanoic Acids
Alternative parentsNaphthalenes; Anisoles; Alkyl Aryl Ethers; Enolates; Carboxylic Acids; Polyamines
Substituentsanisole; phenol ether; alkyl aryl ether; benzene; ether; carboxylic acid; carboxylic acid derivative; polyamine; enolate
Classification descriptionThis compound belongs to the phenylpropanoic acids. These are compounds whose structure contain a benzene ring conjugated to a propanoic acid.
Pharmacology
IndicationFor the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, and acute gout. Also for the relief of mild to moderate pain and the treatment of primary dysmenorrhea.
PharmacodynamicsNaproxen is a member of the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Naproxen has analgesic and antipyretic properties. As with other NSAIDs, its mode of action is not fully understood; however, its ability to inhibit prostaglandin synthesis may be involved in the anti-inflammatory effect.
Mechanism of actionThe mechanism of action of naproxen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammals. The constitutive cyclooxygenase, COX-1, synthesizes prostaglandins necessary for normal gastrointestinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is thought to be associated with gastrointestinal and renal toxicity while inhibition of COX-2 provides anti-inflammatory activity.
AbsorptionNaproxen itself is rapidly and completely absorbed from the GI tract with an in vivo bioavailability of 95%. Although naproxen itself is well absorbed, the sodium salt form is more rapidly absorbed resulting in higher peak plasma levels for a given dose. Food causes a slight decrease in the rate absorption.
Volume of distributionNot Available
Protein bindingAt therapeutic levels naproxen is greater than 99% albumin-bound.
Metabolism

Naproxen is extensively metabolized to 6-0-desmethyl naproxen and both parent and metabolites do not induce metabolizing enzymes.

SubstrateEnzymesProduct
Naproxen
O-DesmethylnaproxenDetails
Naproxen
Naproxen O-glucuronideDetails
O-Desmethylnaproxen
O-Desmethylnaproxen sulfateDetails
O-Desmethylnaproxen
O-Desmethylnaproxen acyl glucuronideDetails
O-Desmethylnaproxen
O-Desmethylnaproxen O-glucuronideDetails
Route of eliminationNot Available
Half lifeThe observed terminal elimination half-life is approximately 15 hours.
ClearanceNot Available
ToxicityORAL (LD50): Acute: 248 mg/kg [Rat]. 360 mg/kg [Mouse]. Symptoms of overdose include drowsiness, heartburn, indigestion, nausea, and vomiting.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9948
Blood Brain Barrier + 0.6881
Caco-2 permeable + 0.9091
P-glycoprotein substrate Non-substrate 0.586
P-glycoprotein inhibitor I Non-inhibitor 0.8747
P-glycoprotein inhibitor II Non-inhibitor 0.8396
Renal organic cation transporter Non-inhibitor 0.8615
CYP450 2C9 substrate Non-substrate 0.7548
CYP450 2D6 substrate Non-substrate 0.9116
CYP450 3A4 substrate Non-substrate 0.5715
CYP450 1A2 substrate Inhibitor 0.9107
CYP450 2C9 substrate Non-inhibitor 0.907
CYP450 2D6 substrate Non-inhibitor 0.9521
CYP450 2C19 substrate Non-inhibitor 0.9447
CYP450 3A4 substrate Non-inhibitor 0.8905
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8598
Ames test AMES toxic 0.5184
Carcinogenicity Non-carcinogens 0.8685
Biodegradation Not ready biodegradable 0.7809
Rat acute toxicity 2.4579 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9588
hERG inhibition (predictor II) Non-inhibitor 0.9144
Pharmacoeconomics
Manufacturers
  • Roche palo alto llc
  • Roxane laboratories inc
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Pliva inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Amneal pharmaceuticals ny llc
  • Baxter healthcare corp anesthesia and critical care
  • Dava pharmaceuticals inc
  • Glenmark generics ltd
  • Hamilton pharmaceuticals ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Perrigo r and d co
  • Purepac pharmaceutical co
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Westward pharmaceutical corp
  • Zydus pharmaceuticals usa inc
  • Banner pharmacaps inc
  • Stat trade inc
  • Watson laboratories inc florida
  • Bayer healthcare llc
  • Able laboratories inc
  • Contract pharmacal corp
  • Dr reddys laboratories inc
  • Dr reddys laboratories ltd
  • Hikma pharmaceuticals
  • L perrigo co
Packagers
Dosage forms
FormRouteStrength
SuppositoryRectal
SuspensionOral
TabletOral
Tablet, coatedOral
Tablet, extended releaseOral
Prices
Unit descriptionCostUnit
Naproxen 125 mg/5ml Suspension 500ml Bottle51.5USDbottle
Naprelan 750 mg 24 Hour tablet8.87USDtablet
Naprelan cr 500 mg tablet8.5USDtablet
Naprelan cr 750 mg tablet8.02USDtablet
Naprelan cr dosecrd 500-750 mg5.98USDeach
Naprelan 375 mg 24 Hour tablet4.34USDtablet
Anaprox ds 550 mg tablet3.66USDtablet
Naprelan 500 mg 24 Hour tablet3.63USDtablet
Naprelan cr 375 mg tablet3.52USDtablet
Naproxen sodium powder2.63USDg
Anaprox 275 mg tablet2.52USDtablet
Naprosyn 500 mg tablet2.42USDtablet
Naproxen powder2.26USDg
Naprosyn 500 mg tablet ec2.19USDtablet
Naprosyn 375 mg tablet1.93USDtablet
Ec-naprosyn 375 mg tablet ec1.79USDtablet
Naprosyn 250 mg tablet1.47USDtablet
Naprosyn Sr 750 mg Sustained-Release Tablet1.43USDtablet
Anaprox Ds 550 mg Tablet1.33USDtablet
Naproxen 500 mg tablet1.32USDtablet
Naproxen sodium 550 mg tablet1.32USDtablet
Naproxen DR 500 mg Enteric Coated Tabs1.3USDtab
Naproxen DR 375 mg Enteric Coated Tabs1.11USDtab
Naprosyn E 500 mg Enteric-Coated Tablet1.09USDtablet
Naproxen 375 mg tablet1.08USDtablet
Apo-Naproxen Sr 750 mg Sustained-Release Tablet1.05USDtablet
Pms-Naproxen 500 mg Suppository0.87USDsuppository
Naproxen sodium 275 mg tablet0.86USDtablet
Naproxen 250 mg tablet0.79USDtablet
Apo-Napro-Na Ds 550 mg Tablet0.7USDtablet
Novo-Naprox Sodium Ds 550 mg Tablet0.7USDtablet
Anaprox 275 mg Tablet0.69USDtablet
Apo-Naproxen Ec 500 mg Enteric-Coated Tablet0.61USDtablet
Mylan-Naproxen Ec 500 mg Enteric-Coated Tablet0.61USDtablet
Novo-Naprox Ec 500 mg Enteric-Coated Tablet0.61USDtablet
Pms-Naproxen Ec 500 mg Enteric-Coated Tablet0.61USDtablet
Naprosyn E 375 mg Enteric-Coated Tablet0.6USDtablet
Naprosyn E 250 mg Enteric-Coated Tablet0.46USDtablet
Apo-Napro-Na 275 mg Tablet0.36USDtablet
Novo-Naprox Sodium 275 mg Tablet0.36USDtablet
Apo-Naproxen Ec 375 mg Enteric-Coated Tablet0.34USDtablet
Mylan-Naproxen Ec 375 mg Enteric-Coated Tablet0.34USDtablet
Novo-Naprox Ec 375 mg Enteric-Coated Tablet0.34USDtablet
Pms-Naproxen Ec 375 mg Enteric-Coated Tablet0.34USDtablet
Apo-Naproxen Ec 250 mg Enteric-Coated Tablet0.26USDtablet
Novo-Naprox Ec 250 mg Enteric-Coated Tablet0.26USDtablet
Apo-Naproxen 500 mg Tablet0.22USDtablet
Novo-Naprox 500 mg Tablet0.22USDtablet
Nu-Naprox 500 mg Tablet0.22USDtablet
Aleve 220 mg gelcap0.19USDcapsule
Naprosyn 125 mg/5ml Suspension0.18USDml
Mediproxen tablet0.17USDtablet
Apo-Naproxen 375 mg Tablet0.15USDtablet
Naproxen sodium 220 mg tablet0.15USDtablet
Novo-Naprox 375 mg Tablet0.15USDtablet
Nu-Naprox 375 mg Tablet0.15USDtablet
CVS Pharmacy all day pain rlf 220 mg tb0.12USDtablet
Wal-proxen 220 mg tablet0.12USDtablet
Apo-Naproxen 250 mg Tablet0.11USDtablet
Novo-Naprox 250 mg Tablet0.11USDtablet
Nu-Naprox 250 mg Tablet0.11USDtablet
All day pain rlf 220 mg caplet0.1USDcaplet
Aleve 220 mg caplet0.09USDcaplet
Aleve 220 mg tablet0.09USDtablet
Wal-proxen 220 mg caplet0.09USDtablet
Apo-Naproxen 125 mg Tablet0.08USDtablet
All day pain relief 220 mg tablet0.07USDtablet
Naprosyn 25 mg/ml Suspension0.07USDml
Naproxen sodium 220 mg caplet0.06USDtablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States56373201994-06-102014-06-10
Canada20340962002-03-262011-01-14
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point153 °CPhysProp
water solubility15.9 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.18HANSCH,C ET AL. (1995)
logS-4.16ADME Research, USCD
Caco2 permeability-4.83ADME Research, USCD
pKa4.15SANGSTER (1994)
Predicted Properties
PropertyValueSource
water solubility5.11e-02 g/lALOGPS
logP3.29ALOGPS
logP2.99ChemAxon
logS-3.6ALOGPS
pKa (strongest acidic)4.19ChemAxon
pKa (strongest basic)-4.8ChemAxon
physiological charge-1ChemAxon
hydrogen acceptor count3ChemAxon
hydrogen donor count1ChemAxon
polar surface area46.53ChemAxon
rotatable bond count3ChemAxon
refractivity64.85ChemAxon
polarizability24.81ChemAxon
number of rings2ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterYesChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraMS/MSLC-MS1D NMR2D NMR
References
Synthesis Reference

DrugSyn.org

US4009197
General Reference
  1. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006 Jun 3;332(7553):1302-8. Pubmed
  2. Zhang J, Ding EL, Song Y: Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006 Oct 4;296(13):1619-32. Epub 2006 Sep 12. Pubmed
External Links
ResourceLink
KEGG DrugD00118
KEGG CompoundC01517
BindingDB50009860
ChEBI7476
ChEMBLCHEMBL154
Therapeutic Targets DatabaseDAP000968
PharmGKBPA450595
Drug Product Database618721
RxListhttp://www.rxlist.com/cgi/generic/naproxsod.htm
Drugs.comhttp://www.drugs.com/naproxen.html
PDRhealthhttp://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ana1021.shtml
WikipediaNaproxen
ATC CodesG02CC02M01AE02M02AA12
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelshow(240 KB)
MSDSshow(75.4 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolThe NSAID, naproxen, may increase the anticoagulant effect of acenocoumarol.
AlendronateIncreased risk of gastric toxicity
AnisindioneThe NSAID, naproxen, may increase the anticoagulant effect of anisindione.
ApixabanDue to pharmacodynamic interaction, a 50-60% increase in anti-Factor Xa activity may be observed with concomitant therapy.
Azilsartan medoxomilIncreases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism.
ColesevelamBile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.
CyclosporineMonitor for nephrotoxicity
DicoumarolThe NSAID, naproxen, may increase the anticoagulant effect of dicumarol.
Ginkgo bilobaAdditive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
LithiumThe NSAID, naproxen, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
MethotrexateThe NSAID, naproxen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
PralatrexateNSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate.
TapentadolIncreases the AUC of tapentadol by 17%. These changes are not considered clinically relevant and no change in dose is required.
TelmisartanConcomitant use of Telmisartan and Naproxen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment.
TimololThe NSAID, Naproxen, may antagonize the antihypertensive effect of Timolol.
TrandolaprilThe NSAID, Naproxen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Naproxen is initiated, discontinued or dose changed.
TreprostinilThe prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Naproxen. Monitor for increased bleeding during concomitant thearpy.
TriflusalThe metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of naproxen to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination.
VilazodoneIncreased risk of bleeding with concomitant use of NSAIDs with vilazodone.
WarfarinThe antiplatelet effects of naproxen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy.
Food Interactions
  • Avoid alcohol.
  • Take with a full glass of water.
  • Take with food.

Targets

1. Prostaglandin G/H synthase 2

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Prostaglandin G/H synthase 2 P35354 Details

References:

  1. Albertini R, Aimbire F, Villaverde AB, Silva JA Jr, Costa MS: COX-2 mRNA expression decreases in the subplantar muscle of rat paw subjected to carrageenan-induced inflammation after low level laser therapy. Inflamm Res. 2007 Jun;56(6):228-9. Pubmed
  2. Dhir A, Naidu PS, Kulkarni SK: Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure. 2007 Jun 29;. Pubmed
  3. Kumar P, Padi SS, Naidu PS, Kumar A: Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam Clin Pharmacol. 2007 Jun;21(3):297-306. Pubmed
  4. White WB: Cardiovascular effects of the selective cyclooxygenase-2 inhibitors. Subcell Biochem. 2007;42:145-58. Pubmed
  5. Hassan-Alin M, Naesdal J, Nilsson-Pieschl C, Langstrom G, Andersson T: Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. Clin Drug Investig. 2005;25(11):731-40. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Prostaglandin G/H synthase 1

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Prostaglandin G/H synthase 1 P23219 Details

References:

  1. James MJ, Cook-Johnson RJ, Cleland LG: Selective COX-2 Inhibitors, Eicosanoid Synthesis and Clinical Outcomes: A Case Study of System Failure. Lipids. 2007 Jun 2;. Pubmed

Enzymes

1. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 2C8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. UDP-glucuronosyltransferase 1-1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 1-1 P22309 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

5. UDP-glucuronosyltransferase 2B7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 2B7 P16662 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

Carriers

1. Serum albumin

Kind: protein

Organism: Human

Pharmacological action: no

Components

Name UniProt ID Details
Serum albumin P02768 Details

References:

  1. Banerjee T, Singh SK, Kishore N: Binding of naproxen and amitriptyline to bovine serum albumin: biophysical aspects. J Phys Chem B. 2006 Nov 30;110(47):24147-56. Pubmed

Transporters

1. Solute carrier organic anion transporter family member 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 1A2 P46721 Details

References:

  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. Pubmed

2. Solute carrier family 22 member 6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 6 Q4U2R8 Details

References:

  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. Pubmed
  2. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 08, 2013 14:24